Comparing Liver Health in Psoriatic Arthritis Treatments
Part of Bones, joints & muscles, Digestive system, Skin clinical trials.
This study looks at how two different types of biologic treatments (anti-TNF and anti-IL-17) affect the liver in people with psoriatic arthritis. It compares their liver health to those on methotrexate alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have psoriatic arthritis (PsA) diagnosed by a doctor.
- You have been on a specific treatment (like anti-TNF, anti-IL-17, or methotrexate alone) for at least 2 years.
- Your past medical records (including liver ultrasound and blood tests) are available for the study team to review.
- You do not have any other chronic liver disease (like hepatitis) and you do not drink heavy amounts of alcohol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if methotrexate (a medicine used for certain immune and skin conditions) causes liver scarring. It uses a special ultrasound and blood tests to look for early signs of liver damage.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study looks at how people with psoriatic arthritis respond to different types of biologic or targeted synthetic drugs. Participants will be starting a new treatment, and the study will check both clinical symptoms and immune system changes over time.
This study looks at whether the drug guselkumab can help people who have both psoriatic arthritis and non-alcoholic fatty liver disease (NAFLD). If you are starting guselkumab for your psoriatic arthritis and have a fatty liver, you may be able to join.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.